ATE215822T1 - Verwendung von rapamycin zur behandlung von anämie - Google Patents

Verwendung von rapamycin zur behandlung von anämie

Info

Publication number: ATE215822T1
Authority: AT; Austria
Prior art keywords: rapamycin; treat anemia; mammal; anemia; intrabronchially
Prior art date: 1994-12-13

Application number

AT95308503T

Other languages

English (en)

Inventor

Jay Joseph Armstrong

Original Assignee

American Home Prod

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-12-13

Filing date

1995-11-27

Publication date

2002-04-15

1995-11-27 Application filed by American Home Prod filed Critical American Home Prod

2002-04-15 Application granted granted Critical

2002-04-15 Publication of ATE215822T1 publication Critical patent/ATE215822T1/de

Links

208000007502 anemia Diseases 0.000 title abstract 2
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 title abstract 2
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title abstract 2
229960002930 sirolimus Drugs 0.000 title abstract 2
241000124008 Mammalia Species 0.000 abstract 2

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Diabetes (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Hematology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AT95308503T 1994-12-13 1995-11-27 Verwendung von rapamycin zur behandlung von anämie ATE215822T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US08/354,977 US5561138A (en)	1994-12-13	1994-12-13	Method of treating anemia

Publications (1)

Publication Number	Publication Date
ATE215822T1 true ATE215822T1 (de)	2002-04-15

Family

ID=23395715

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT95308503T ATE215822T1 (de)	1994-12-13	1995-11-27	Verwendung von rapamycin zur behandlung von anämie

Country Status (11)

Country	Link
US (1)	US5561138A (de)
EP (1)	EP0716857B1 (de)
JP (1)	JPH08208661A (de)
KR (1)	KR100423825B1 (de)
AT (1)	ATE215822T1 (de)
CA (1)	CA2164921A1 (de)
DE (1)	DE69526311T2 (de)
DK (1)	DK0716857T3 (de)
ES (1)	ES2179862T3 (de)
MX (1)	MX9505187A (de)
PT (1)	PT716857E (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1289815B1 (it) *	1996-12-30	1998-10-16	Sorin Biomedica Cardio Spa	Stent per angioplastica e relativo procedimento di produzione
US6667300B2 (en)	2000-04-25	2003-12-23	Icos Corporation	Inhibitors of human phosphatidylinositol 3-kinase delta
US6670355B2 (en)	2000-06-16	2003-12-30	Wyeth	Method of treating cardiovascular disease
JP2004509898A (ja)	2000-09-19	2004-04-02	ワイス	水溶性ラパマイシンエステル
US6399625B1 (en)	2000-09-27	2002-06-04	Wyeth	1-oxorapamycins
US6399626B1 (en)	2000-10-02	2002-06-04	Wyeth	Hydroxyesters of 7-desmethylrapamycin
US6440991B1 (en)	2000-10-02	2002-08-27	Wyeth	Ethers of 7-desmethlrapamycin
TWI286074B (en)	2000-11-15	2007-09-01	Wyeth Corp	Pharmaceutical composition containing CCI-779 as an antineoplastic agent
TWI296196B (en) *	2001-04-06	2008-05-01	Wyeth Corp	Antineoplastic combinations
TWI233359B (en) *	2001-04-06	2005-06-01	Wyeth Corp	Pharmaceutical composition for treating neoplasm
US20020198137A1 (en) *	2001-06-01	2002-12-26	Wyeth	Antineoplastic combinations
UA77200C2 (en)	2001-08-07	2006-11-15	Wyeth Corp	Antineoplastic combination of cci-779 and bkb-569
EP1419154B1 (de)	2001-08-22	2005-10-05	Wyeth	Rapanycin29-enole
US6680330B2 (en)	2001-08-22	2004-01-20	Wyeth	Rapamycin dialdehydes
RU2344821C2 (ru) *	2002-07-30	2009-01-27	Уайт	Парентеральные композиции, содержащие гидроксиэфиры рапамицина
UA81265C2 (en) *	2002-09-17	2007-12-25	Wyeth Corp	Granulate formulation of the rapamycin ester cci-779 and process for the preparation thereof
AR042938A1 (es) *	2003-02-06	2005-07-06	Wyeth Corp	Uso del cci-779 en el tratamiento de la fibrosis hepatica
UA83484C2 (uk) *	2003-03-05	2008-07-25	Уайт	Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
KR20060006058A (ko) *	2003-04-22	2006-01-18	와이어쓰	항신생물성 배합물
LT2612862T (lt)	2004-05-13	2017-01-25	Icos Corporation	Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės delta inhibitoriai
WO2005117889A1 (en) *	2004-05-25	2005-12-15	Icos Corporation	Methods for treating and/or preventing aberrant proliferation of hematopoietic
CA2582374A1 (en) *	2004-10-04	2006-04-20	Qlt Usa, Inc.	Ocular delivery of polymeric delivery formulations
US8313763B2 (en) *	2004-10-04	2012-11-20	Tolmar Therapeutics, Inc.	Sustained delivery formulations of rapamycin compounds
AU2006315512B2 (en)	2005-11-14	2012-11-01	Ariad Pharmaceuticals, Inc.	Administration of an mTOR inhibitor to treat patients with cancer
WO2008022256A2 (en) *	2006-08-16	2008-02-21	Blagosklonny Mikhail V	Methods and compositions for preventing or treating age-related diseases
US7867988B2 (en)	2006-09-13	2011-01-11	Elixir Medical Corporation	Macrocyclic lactone compounds and methods for their use
EP2352459A4 (de) *	2008-10-03	2013-09-25	Elixir Medical Corp	Makrocyclische lactonverbindungen und verfahren zu ihrer verwendung
CA2937492C (en)	2008-11-11	2019-08-13	The Board Of Regents Of The University Of Texas System	Inhibition of mammalian target of rapamycin
US9492449B2 (en)	2008-11-13	2016-11-15	Gilead Calistoga Llc	Therapies for hematologic malignancies
KR20170060179A (ko)	2008-11-13	2017-05-31	길리아드 칼리스토가 엘엘씨	혈액 종양에 대한 요법
AU2010229968A1 (en)	2009-03-24	2011-10-13	Gilead Calistoga Llc	Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
WO2010118419A2 (en)	2009-04-10	2010-10-14	Haiyan Qi	Novel anti-aging agents and methods to identify them
JP2012524126A (ja)	2009-04-20	2012-10-11	ギリアドカリストガリミテッドライアビリティカンパニー	固形腫瘍の治療方法
CA2768843A1 (en)	2009-07-21	2011-01-27	Gilead Calistoga Llc	Treatment of liver disorders with pi3k inhibitors
US9364507B2 (en)	2009-08-11	2016-06-14	Imagilin Technology, Llc	Probiotic enhancement of steroid and immune suppressor activity in mammals with chronic diseases
US9283211B1 (en)	2009-11-11	2016-03-15	Rapamycin Holdings, Llc	Oral rapamycin preparation and use for stomatitis
US10391059B2 (en)	2009-11-11	2019-08-27	Rapamycin Holdings, Inc.	Oral rapamycin nanoparticle preparations and use
ES2848273T3 (es)	2012-03-05	2021-08-06	Gilead Calistoga Llc	Formas polimórficas de (S)-2-(1-(9H-purin-6-ilamino)propilo)-5-fluoro-3-fenilquinazolina-4(3H)-ona
US20150290176A1 (en)	2012-10-12	2015-10-15	The Board Of Regents Of The University Of Texas System	Use of mtor inhibitors to treat vascular cognitive impairment
US20160030401A1 (en)	2013-03-13	2016-02-04	The Board Of Regents Of The University Of Texas System	Use of mtor inhibitors for prevention of intestinal polyp growth and cancer
JP2017500319A (ja)	2013-12-20	2017-01-05	ギリアードカリストガエルエルシー	（ｓ）−２−（１−（９ｈ−プリン−６−イルアミノ）プロピル）−５−フルオロ−３−フェニルキナゾリン−４（３ｈ）−オンの塩酸塩の多形形態
EP3083630B1 (de)	2013-12-20	2019-08-21	Gilead Calistoga LLC	Prozessverfahren für phosphatidylinositol-3-kinase-hemmer
US9700544B2 (en)	2013-12-31	2017-07-11	Neal K Vail	Oral rapamycin nanoparticle preparations
US11021467B2 (en)	2014-06-13	2021-06-01	Gilead Sciences, Inc.	Phosphatidylinositol 3-kinase inhibitors
CA3177632A1 (en) *	2020-05-15	2021-11-18	Melih ACAR	Methods and compositions for treating anemia using actriib ligand traps and mtor inhibitors
CN116459248B (zh) *	2023-04-27	2024-02-13	中国人民解放军陆军军医大学第二附属医院	雷帕霉素在制备治疗肿瘤相关性贫血的药物中的应用和药物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA737247B (en) *	1972-09-29	1975-04-30	Ayerst Mckenna & Harrison	Rapamycin and process of preparation
US3993749A (en) *	1974-04-12	1976-11-23	Ayerst Mckenna And Harrison Ltd.	Rapamycin and process of preparation
US4885171A (en) *	1978-11-03	1989-12-05	American Home Products Corporation	Use of rapamycin in treatment of certain tumors
US5206018A (en) *	1978-11-03	1993-04-27	Ayerst, Mckenna & Harrison, Inc.	Use of rapamycin in treatment of tumors
US4401653A (en) *	1981-03-09	1983-08-30	Ayerst, Mckenna & Harrison Inc.	Combination of rapamycin and picibanil for the treatment of tumors
US5100899A (en) *	1989-06-06	1992-03-31	Roy Calne	Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
ATE166228T1 (de) *	1990-08-10	1998-06-15	Anormed Inc	Immunosuppressive zusammensetzungen
US5080899A (en) *	1991-02-22	1992-01-14	American Home Products Corporation	Method of treating pulmonary inflammation
US5078999A (en) *	1991-02-22	1992-01-07	American Home Products Corporation	Method of treating systemic lupus erythematosus
IL101353A0 (en) *	1991-04-03	1992-11-15	American Home Prod	Pharmaceutical compositions for treating diabetes
US5321009A (en) *	1991-04-03	1994-06-14	American Home Products Corporation	Method of treating diabetes
US5091389A (en) *	1991-04-23	1992-02-25	Merck & Co., Inc.	Lipophilic macrolide useful as an immunosuppressant
DE69209183T2 (de)	1991-06-18	1996-08-08	American Home Prod	Verwendung von Rapamycin zur Behandlung von T-Zellen Lymphom/Leukämie bei Erwachsenen
ZA924953B (en)	1991-07-25	1993-04-28	Univ Louisville Res Found	Method of treating ocular inflammation
US5286730A (en) *	1991-09-17	1994-02-15	American Home Products Corporation	Method of treating immunoinflammatory disease
US5286731A (en) *	1991-09-17	1994-02-15	American Home Products Corporation	Method of treating immunoinflammatory bowel disease
US5288711A (en) *	1992-04-28	1994-02-22	American Home Products Corporation	Method of treating hyperproliferative vascular disease
GB9221220D0 (en) *	1992-10-09	1992-11-25	Sandoz Ag	Organic componds
GB9302567D0 (en) *	1993-02-10	1993-03-24	Smithkline Beecham Plc	Novel compound
CH686761A5 (de) *	1993-05-27	1996-06-28	Sandoz Ag	Galenische Formulierungen.

1994
- 1994-12-13 US US08/354,977 patent/US5561138A/en not_active Expired - Lifetime
1995
- 1995-11-27 ES ES95308503T patent/ES2179862T3/es not_active Expired - Lifetime
- 1995-11-27 DE DE69526311T patent/DE69526311T2/de not_active Expired - Fee Related
- 1995-11-27 PT PT95308503T patent/PT716857E/pt unknown
- 1995-11-27 AT AT95308503T patent/ATE215822T1/de not_active IP Right Cessation
- 1995-11-27 EP EP95308503A patent/EP0716857B1/de not_active Expired - Lifetime
- 1995-11-27 DK DK95308503T patent/DK0716857T3/da active
- 1995-12-11 CA CA002164921A patent/CA2164921A1/en not_active Abandoned
- 1995-12-11 MX MX9505187A patent/MX9505187A/es unknown
- 1995-12-12 KR KR1019950048544A patent/KR100423825B1/ko not_active Expired - Fee Related
- 1995-12-12 JP JP7323042A patent/JPH08208661A/ja active Pending

Also Published As

Publication number	Publication date
ES2179862T3 (es)	2003-02-01
DE69526311T2 (de)	2002-11-28
MX9505187A (es)	1997-04-30
DE69526311D1 (de)	2002-05-16
US5561138A (en)	1996-10-01
CA2164921A1 (en)	1996-06-14
KR100423825B1 (ko)	2004-06-26
KR960021019A (ko)	1996-07-18
DK0716857T3 (da)	2002-08-05
EP0716857A1 (de)	1996-06-19
JPH08208661A (ja)	1996-08-13
PT716857E (pt)	2002-08-30
EP0716857B1 (de)	2002-04-10
HK1010345A1 (en)	1999-06-17

Legal Events

Date	Code	Title	Description
2002-07-15	UEP	Publication of translation of european patent specification
2007-08-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
DE69526311D1 (de)	2002-05-16	Verwendung von Rapamycin zur Behandlung von Anämie
ATE241358T1 (de)	2003-06-15	Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
ATE362361T1 (de)	2007-06-15	Verfahren zur behandlung vaskulärer kopfschmerzen
ATE448791T1 (de)	2009-12-15	Methoden und zusammensetzungen für die behandlung von glomerulonephritis
DE69434610D1 (de)	2008-08-21	Verwendung der neurotoxischen Komponente des Botulinum Toxins zur Behandlung von Muskelspasmen
DE69528475D1 (de)	2002-11-07	Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
DE60015070D1 (de)	2004-11-25	Verwendung von antikonvulsiven derivaten zur behandlung der cluster headache
NL300180I2 (nl)	2005-08-01	Toepasen van toxmoxetine voor het behandelen van de concentratiestoornis/hyperactiviteit aandoening.
LV10048A (lv)	1994-05-10	Lidzeklis slimibu arstesanai un ta iegusanas process
ATE411016T1 (de)	2008-10-15	Verfahren zur prophylaxis oder behandlung von östrogen-abhängigen krankheiten
ATE205425T1 (de)	2001-09-15	Verfahren zur behandlung von festen abfällen
ATE345811T1 (de)	2006-12-15	Methoden zur verwendung von neurotrophin 3 (nt-3) zur behandlung von gastrointestinalen hypomobilitätsstörungen
DE69822692D1 (de)	2004-05-06	Stabilisierung von flüssigem Kaffee durch Behandlung mit Alkali
DE69608279D1 (de)	2000-06-15	Verfahren zur behandlung von abfallschlamm
EA199800764A1 (ru)	1999-06-24	Способ лечения или предупреждения макулярного отека или возрастной макулярной дистрофии
DE68913456D1 (de)	1994-04-07	Verfahren zur Behandlung von Stahlblech.
DE69721756D1 (de)	2003-06-12	Paroxetine zur behandlung von depression
ATE213163T1 (de)	2002-02-15	Verfahren zur behandlung von motorischen defiziten
DE69114854D1 (de)	1996-01-04	Verfahren zur behandlung von photographischen abwässern.
NO984160D0 (no)	1998-09-10	Fremgangsmåte for behandling eller forebyggelse av interstitiell cystitt
DE69518438D1 (de)	2000-09-21	Behandlung von übereregten nervenzellenfunktionen
DE59206872D1 (de)	1996-09-12	Verwendung von torasemid zur behandlung von hirnödemen
DE69629955D1 (de)	2003-10-16	Verfahren zur behandlung von holz
DE60121815D1 (de)	2006-09-07	System und prozess zur reinigung und/oder behandlung von fahrzeugoberflächen
DE69623767D1 (de)	2002-10-24	Verwendung von pyrrolidinderivaten zur behandlung des alkoholismus